Region
CDMOs in Australia
Compare Australian CDMOs with TGA-approved facilities for biologics, drug products, and analytical services. Filter by manufacturing type, scale, and regulatory approvals.
28 companies listed
Australian CDMO Manufacturing
Australia's pharmaceutical manufacturing sector is compact but high-quality. Key CDMO capabilities include sterile manufacturing, biologics drug product, analytical services, and clinical trial material supply. The TGA (Therapeutic Goods Administration) enforces rigorous GMP standards aligned with PIC/S guidelines, and Australian GMP certificates are recognized internationally.
Government support is strengthening the sector. The Australian government has introduced manufacturing incentives through the Medical Products Priority Round and the Modern Manufacturing Initiative, targeting pharmaceutical sovereignty and pandemic preparedness. These grants reduce the effective cost of establishing or expanding CDMO operations in Australia.
Geographically, Australia offers strategic access to Southeast Asian markets, which represent fast-growing pharmaceutical demand. CDMOs in Australia can serve as a quality-assured manufacturing base for products destined for ASEAN regulatory submissions.
Companies (28)
PCI Pharma Services
Australia
PCI Pharma Services is a global CDMO providing fully integrated drug development, manufacturing, clinical trial services, and commercial packaging solutions. With over 8,000 employees in 38 GMP facilities worldwide, PCI offers services spanning sterile fill-finish, lyophilization, oral solid dose manufacturing, complex formulations, and advanced drug delivery including drug-device combination products.
Small Molecule Drug ProductOral Solid DoseFormulation Development
Sypharma Pty Ltd
Australia
Sypharma is an Australian specialty contract manufacturing group operating since 2005. They develop and manufacture therapeutic goods, veterinary products, and specialty consumer products. They specialize in contract manufacturing for early clinical through Phase III clinical trials and have multipurpose cleanrooms for oral, topical, and parenteral drug products. They manufacture both large and small volume parenterals and have a veterinary manufacturing suite. Licensed by FDA, TGA, and ISO 13485 certified. They partnered with Schott on sterile fill/finish capabilities.
Frequently Asked Questions
What types of pharmaceutical manufacturing exist in Australia?+
Australian CDMOs primarily focus on: sterile drug product manufacturing (injectables, ophthalmic products), small-scale biologics, analytical and stability testing services, clinical trial material manufacturing, and packaging and labeling for regional distribution. Large-scale API synthesis is limited compared to India or China, but niche capabilities in high-potency and sterile products exist.
How does TGA GMP certification benefit international sponsors?+
TGA is a founding member of PIC/S and maintains mutual recognition agreements with the FDA, EMA, Health Canada, and Swissmedic. This means a TGA GMP certificate is widely accepted without additional inspections. For sponsors targeting global markets, Australian manufacturing provides regulatory credibility and reduces the inspection burden compared to facilities in countries without such agreements.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
